Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

about

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

P2860

Q57486479-B72DA094-6998-4E2A-AB7B-5EC68AC13FC3

P2860

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Item

http://www.wikidata.org/entity/Q51768172

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Oncogenic JAK2V617F causes PD- ...... myeloproliferative neoplasms.

@en

Oncogenic JAK2V617F causes PD- ...... myeloproliferative neoplasms.

@nl

type

Item

label

Oncogenic JAK2V617F causes PD- ...... myeloproliferative neoplasms.

@en

Oncogenic JAK2V617F causes PD- ...... myeloproliferative neoplasms.

@nl

prefLabel

Oncogenic JAK2V617F causes PD- ...... myeloproliferative neoplasms.

@en

Oncogenic JAK2V617F causes PD- ...... myeloproliferative neoplasms.

@nl

P1476

Oncogenic JAK2V617F causes PD- ...... n myeloproliferative neoplasms

@en

P2093

Anna L Illert

http://www.w3.org/2001/XMLSchema#string

Christine Dierks

http://www.w3.org/2001/XMLSchema#string

David O'Sullivan

http://www.w3.org/2001/XMLSchema#string

Eliana Ruggiero

http://www.w3.org/2001/XMLSchema#string

Frederike A Hartl

http://www.w3.org/2001/XMLSchema#string

Gabriele Niedermann

http://www.w3.org/2001/XMLSchema#string

Geoffrey R Hill

http://www.w3.org/2001/XMLSchema#string

Justus Duyster

http://www.w3.org/2001/XMLSchema#string

Jürgen Finke

http://www.w3.org/2001/XMLSchema#string

Melanie Boerries

http://www.w3.org/2001/XMLSchema#string

P2860

T cell metabolism drives immunity

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation.

Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease.

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAM7729

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

429

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Prestipino

Mark Bartholomä

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29467301

http://www.w3.org/2001/XMLSchema#string

P932

6034655

http://www.w3.org/2001/XMLSchema#string

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

about

P2860

P2860

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932